QUAD vs SRPT vs BMRN vs ALNY

For growth investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus -9. 4% for Quad/Graphics, Inc. (QUAD). Quad/Graphics, Inc. (QUAD) offers the better valuation at 14. 2x trailing P/E (6. 3x forward), making it the more compelling value choice. Analysts rate Quad/Graphics, Inc. (QUAD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Quad/Graphics, Inc.

(QUAD) is the cheapest at 14. 2x versus Alnylam Pharmaceuticals, Inc. at 127. 0x. On forward P/E, Quad/Graphics, Inc. is actually cheaper at 6. 3x.

Over the past 5 years, Quad/Graphics, Inc.

(QUAD) delivered a total return of +158. 1%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: ALNY returned +411. 9% versus BMRN's -35. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc.

(BMRN) is the lower-risk stock at 0. 65β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 211% more volatile than BMRN relative to the S&P 500. On balance sheet safety, BioMarin Pharmaceutical Inc. (BMRN) carries a lower debt/equity ratio of 11% versus 3% for Quad/Graphics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.

(ALNY) is pulling ahead at 65. 2% versus -9. 4% for Quad/Graphics, Inc. (QUAD). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BioMarin Pharmaceutical Inc.

(BMRN) is the more profitable company, earning 10. 8% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16. 6% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — ALNY leads at 81. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Quad/Graphics, Inc.

(QUAD) trades at 6. 3x forward P/E versus 44. 2x for Alnylam Pharmaceuticals, Inc. — 37. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMRN: 65. 6% to $89. 64.

In this comparison, QUAD (3.

8% yield) pays a dividend. SRPT, BMRN, ALNY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71), +411. 9% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALNY: +411. 9%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (QUAD (Industrials) and SRPT (Healthcare) and BMRN (Healthcare) and ALNY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: QUAD is a small-cap deep-value stock; SRPT is a small-cap high-growth stock; BMRN is a mid-cap quality compounder stock; ALNY is a mid-cap high-growth stock. QUAD pays a dividend while SRPT, BMRN, ALNY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.